Modality
Gene Editing
MOA
VEGFi
Target
WEE1
Pathway
PD-1/PD-L1
MigraineALSFTD
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
Oct 2018
→ Oct 2029
Phase 1Current
NCT04306763
1,733 pts·ALS
2018-10→2029-10·Terminated
1,733 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-10-073.5y awayInterim· ALS
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Termina…
Catalysts
Interim
2029-10-07 · 3.5y away
ALS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04306763 | Phase 1 | ALS | Terminated | 1733 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 |